Digital Health Monthly: Scientific Webinar Series
DECODE Obesity: Advancing Digital Endpoints for the Next Generation of Treatments
Thursday, September 18, 2025 @ 12 PM ET
Upcoming Digital Health Monthly:
Scientific Webinar Series
Accelerating DHT Research and Drug Development with Open-Source Big Data from Population Studies
Tuesday, December 3 @ 12 PM ET
Digital Health Monthly: Scientific Webinar Series
Sensor-based DHTs are shedding an illuminating light on how people function in their real-world environments. Drug developers, researchers, patients, and regulators are realizing the multifaceted value sensor-based DHTs can bring to clinical research.
As their adoption continues to grow, the ActiGraph team is excited to continue ‘Digital Health Monthly’, a monthly series of science-focused webinars to share the latest high-impact developments in clinical research from innovators in the digital health field. Each month, we feature brief data-driven presentations from clinical researchers, data scientists, and biostatisticians on a focused topic with dedicated time for audience Q&A. We believe that together, we can move the digital health technology field forward faster, and we are excited for this opportunity to facilitate important discussions on the latest research with members of the digital health community.
GLP-1 treatments have profoundly transformed the landscape of obesity drug development. While treatments are becoming more potent and their applications are expanding to include more indications, accounting for treatment benefit in addition to weight loss has become increasingly important to optimize program success, differentiate treatments, and support payer negotiations. That’s why Ametris (formerly ActiGraph) is excited to launch publicly the cross-industry initiative: (DECODE) in Obesity.
This cross-industry collaboration between founding partners Eli Lilly, F. Hoffman La Roche, and Novo Nordisk and Ametris will focus on evidence generation and regulatory engagement to enhance clinical programs in obesity with mature assessments of physical activity and function.
During this session of Digital Health Monthly, we’ll describe the workstreams and goals of the DECODE Obesity working group. Then, working group members will discuss why they joined DECODE Obesity, what is needed for DHTs to reach full utility in clinical trials, and the pros and cons of different approaches to developing and validating DHTs for use in clinical development.
